| 应用 |
A selective large conductance calcium activated potassium channel activator |
| 产品介绍 |
BIIB021(CNF2024)是口服活性的HSP90抑制剂，Ki和EC50分别为1.7 nM和38 nM。 |
| 备注 |
BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. |
| 生化机理 |
Oral administration of BIIB021 leads to tumor growth inhibition in many tumor xenograft models including N87, BT474, CWR22, U87, SKOV3 and Panc-1. BIIB021 effectively inhibits growth of L540cy tumor at a dose of 120 mg/kg. BIIB021 significantly enhances antitumor growth effect of radiation in JHU12 xenograft. |
| 别名 |
BIIB-021; BIIB 021; 6-氯-9-((4-甲氧基-3,5-二甲基-2-吡啶基)甲基)-9H-嘌呤-2-胺;;CNF2024; ;CNF 2024;CNF-2024;6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)-9h-purin-2-amine;1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one |
